What’s new in 2022 regarding expansion in atypical HUS knowledge, and advancements for investigational drugs which may have potential as new aHUS therapeutic treatments? As with most matters, COVID-19 priorities slowed down research and initiatives specific to atypical HUS. It’s been a scattered yet productive couple of years since our last overview in 2020 regarding the aHUS pipeline and drug discovery, so the aHUS Alliance Global Action team has again scanned this horizon while retaining our unique and independent patients’ perspective.
Click HERE to view the entire article about clinical trials, information regarding potential drug candidates, and insight into issues which face patients, physicians, and pharma. Complete with our 2022 chart of potential new aHUS therapeutic drug candidates.
https://bit.ly/aHUS2022drugReview
